These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 10752674)

  • 21. Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects.
    Chen XP; Tan ZR; Huang SL; Huang Z; Ou-Yang DS; Zhou HH
    Clin Pharmacol Ther; 2003 Mar; 73(3):264-71. PubMed ID: 12621391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human cytochrome P450-catalyzed conversion of the proestrogenic pesticide methoxychlor into an estrogen. Role of CYP2C19 and CYP1A2 in O-demethylation.
    Stresser DM; Kupfer D
    Drug Metab Dispos; 1998 Sep; 26(9):868-74. PubMed ID: 9733665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes.
    Fang J; McKay G; Song J; Remillrd A; Li X; Midha K
    Drug Metab Dispos; 2001 Dec; 29(12):1638-43. PubMed ID: 11717183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4.
    Feierman DE; Lasker JM
    Drug Metab Dispos; 1996 Sep; 24(9):932-9. PubMed ID: 8886601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
    Wen X; Wang JS; Neuvonen PJ; Backman JT
    Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
    Mankowski DC
    Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of honey on CYP3A4, CYP2D6 and CYP2C19 enzyme activity in healthy human volunteers.
    Tushar T; Vinod T; Rajan S; Shashindran C; Adithan C
    Basic Clin Pharmacol Toxicol; 2007 Apr; 100(4):269-72. PubMed ID: 17371531
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
    Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
    Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.
    Kazui M; Nishiya Y; Ishizuka T; Hagihara K; Farid NA; Okazaki O; Ikeda T; Kurihara A
    Drug Metab Dispos; 2010 Jan; 38(1):92-9. PubMed ID: 19812348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Asymmetric redox reactions in human liver stereoselective oxidation of optically active dihydrohaloperidols, dihydrobromoperidols and stereospecific reduction of haloperidol and bromoperidol.
    Takeshita M; Miura M; Ohkubo T; Sugawara K
    Enantiomer; 2000; 5(2):189-95. PubMed ID: 10857058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prosubstrates of CYP3A4, the major human hepatic cytochrome P450: transformation into substrates by other P450 isoforms.
    Stresser DM; Kupfer D
    Biochem Pharmacol; 1998 Jun; 55(11):1861-71. PubMed ID: 9714305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes.
    Bellec G; Dréano Y; Lozach P; Ménez JF; Berthou F
    Carcinogenesis; 1996 Sep; 17(9):2029-34. PubMed ID: 8824531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
    Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
    Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition selectivity of grapefruit juice components on human cytochromes P450.
    Tassaneeyakul W; Guo LQ; Fukuda K; Ohta T; Yamazoe Y
    Arch Biochem Biophys; 2000 Jun; 378(2):356-63. PubMed ID: 10860553
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitory effects of gypenosides on seven human cytochrome P450 enzymes in vitro.
    He M; Jiang J; Qiu F; Liu S; Peng P; Gao C; Miao P
    Food Chem Toxicol; 2013 Jul; 57():262-5. PubMed ID: 23583485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The interactions of a selective protein kinase C beta inhibitor with the human cytochromes P450.
    Ring BJ; Gillespie JS; Binkley SN; Campanale KM; Wrighton SA
    Drug Metab Dispos; 2002 Sep; 30(9):957-61. PubMed ID: 12167559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of irsogladine on P450-isoform specific activities in human hepatic microsomes.
    Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Nonaka K; Mukai H
    Arzneimittelforschung; 2006; 56(7):547-52. PubMed ID: 16927538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
    Ramírez J; Innocenti F; Schuetz EG; Flockhart DA; Relling MV; Santucci R; Ratain MJ
    Drug Metab Dispos; 2004 Sep; 32(9):930-6. PubMed ID: 15319333
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of cytochrome P450 activity by a five-drug cocktail approach.
    Zhu B; Ou-Yang DS; Chen XP; Huang SL; Tan ZR; He N; Zhou HH
    Clin Pharmacol Ther; 2001 Nov; 70(5):455-61. PubMed ID: 11719732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human cytochrome P450s: selectivity and measurement in vivo.
    Smith DA; Abel SM; Hyland R; Jones BC
    Xenobiotica; 1998 Dec; 28(12):1095-128. PubMed ID: 9890156
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.